Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors.


Journal

JAMA surgery
ISSN: 2168-6262
Titre abrégé: JAMA Surg
Pays: United States
ID NLM: 101589553

Informations de publication

Date de publication:
01 11 2020
Historique:
pubmed: 17 9 2020
medline: 7 2 2021
entrez: 16 9 2020
Statut: ppublish

Résumé

Young women with breast cancer are increasingly choosing bilateral mastectomy (BM), yet little is known about short-term and long-term physical and psychosocial well-being following surgery in this population. To evaluate the differential associations of surgery with quality of life (QOL) and psychosocial outcomes from 1 to 5 years following diagnosis. Cohort study. Multicenter, including academic and community hospitals in North America. Women age ≤40 when diagnosed with Stage 0-3 with unilateral breast cancer between 2006 and 2016 who had surgery and completed QOL and psychosocial assessments. Primary breast surgery including breast-conserving surgery (BCS), unilateral mastectomy (UM), and BM. Physical functioning, body image, sexual health, anxiety and depressive symptoms were assessed in follow-up. Of 826 women, mean age at diagnosis was 36.1 years; most women were White non-Hispanic (86.7%). Regarding surgery, 45% had BM, 31% BCS, and 24% UM. Of women who had BM/UM, 84% had reconstruction. While physical functioning, sexuality, and body image improved over time, sexuality and body image were consistently worse (higher adjusted mean scores) among women who had BM vs BCS (body image: year 1, 1.32 vs 0.64; P < .001; year 5, 1.19 vs 0.48; P < .001; sexuality: year 1, 1.66 vs 1.20, P < .001; year 5, 1.43 vs 0.96; P < .001) or UM (body image: year 1, 1.32 vs 1.15; P = .06; year 5, 1.19 vs 0.96; P = .02; sexuality: year 1, 1.66 vs 1.41; P = .02; year 5, 1.43 vs 1.09; P = .002). Anxiety improved across groups, but adjusted mean scores remained higher among women who had BM vs BCS/UM at 1 year (BM, 7.75 vs BCS, 6.94; P = .005; BM, 7.75 vs UM, 6.58; P = .005), 2 years (BM, 7.47 vs BCS, 6.18; P < .001; BM, 7.47 vs UM, 6.07; P < .001) and 5 years (BM, 6.67 vs BCS, 5.91; P = .05; BM, 6.67 vs UM, 5.79; P = .05). There were minimal between-group differences in depression levels in follow-up. While QOL improves over time, young breast cancer survivors who undergo more extensive surgery have worse body image, sexual health, and anxiety compared with women undergoing less extensive surgery. Ensuring young women are aware of the short-term and long-term effects of surgery and receive support when making surgical decisions is warranted.

Identifiants

pubmed: 32936216
pii: 2770271
doi: 10.1001/jamasurg.2020.3325
pmc: PMC7495332
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1035-1042

Subventions

Organisme : AHRQ HHS
ID : K01 HS023680
Pays : United States

Références

Ann Surg Oncol. 1999 Sep;6(6):546-52
pubmed: 10493622
Ann Surg Oncol. 2013 Dec;20(13):4113-20
pubmed: 23868655
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Clin Oncol. 2018 Sep 1;36(25):2630-2638
pubmed: 30044695
J Clin Oncol. 2006 Mar 20;24(9):1350-6
pubmed: 16549829
J Clin Oncol. 2016 May 1;34(13):1518-27
pubmed: 26951322
Ann Surg Oncol. 2017 Jun;24(6):1499-1506
pubmed: 28058563
J Clin Oncol. 2005 Nov 1;23(31):7849-56
pubmed: 16204003
Lancet Oncol. 2013 Jun;14(7):e262-9
pubmed: 23725708
Cancer. 1991 Sep 15;68(6):1406-13
pubmed: 1873793
Ann Surg. 2017 Mar;265(3):581-589
pubmed: 28169929
J Natl Cancer Inst. 2012 Mar 7;104(5):386-405
pubmed: 22271773
Ann Surg Oncol. 2015 Nov;22(12):3809-15
pubmed: 25930247
JAMA Surg. 2017 Jul 1;152(7):648-657
pubmed: 28355431
Ann Intern Med. 2013 Sep 17;159(6):373-81
pubmed: 24042365
Breast Cancer Res Treat. 2013 Aug;140(3):447-52
pubmed: 23893127
Ann Surg Oncol. 2013 Oct;20(10):3212-7
pubmed: 23846780
JAMA. 2014 Sep 3;312(9):902-14
pubmed: 25182099
Psychooncology. 2019 Feb;28(2):394-400
pubmed: 30500102

Auteurs

Shoshana M Rosenberg (SM)

Dana-Farber Cancer Institute, Boston, Massachusetts.

Laura S Dominici (LS)

Brigham and Women's Hospital, Boston, Massachusetts.

Shari Gelber (S)

Dana-Farber Cancer Institute, Boston, Massachusetts.

Philip D Poorvu (PD)

Dana-Farber Cancer Institute, Boston, Massachusetts.

Kathryn J Ruddy (KJ)

Mayo Clinic, Rochester, Minnesota.

Julia S Wong (JS)

Dana-Farber Cancer Institute, Boston, Massachusetts.

Rulla M Tamimi (RM)

Brigham and Women's Hospital, Boston, Massachusetts.

Lidia Schapira (L)

Stanford University, Stanford, California.

Steven Come (S)

Beth Israel Deaconess, Boston, Massachusetts.

Jeffrey M Peppercorn (JM)

Massachusetts General Hospital, Boston, Massachusetts.

Virginia F Borges (VF)

University of Colorado Cancer Center, Denver.

Ann H Partridge (AH)

Dana-Farber Cancer Institute, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH